IRIS Accounts Production v26.1.0.640 14793248 director 1.8.24 31.7.25 31.7.25 false true false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 14793248 2024-07-31 14793248 2025-07-31 14793248 2024-08-01 2025-07-31 14793248 2023-04-10 14793248 2023-04-11 2024-07-31 14793248 2024-07-31 14793248 ns15:EnglandWales 2024-08-01 2025-07-31 14793248 ns14:PoundSterling 2024-08-01 2025-07-31 14793248 ns10:Director1 2024-08-01 2025-07-31 14793248 ns10:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 14793248 ns10:SmallEntities 2024-08-01 2025-07-31 14793248 ns10:AuditExempt-NoAccountantsReport 2024-08-01 2025-07-31 14793248 ns10:SmallCompaniesRegimeForDirectorsReport 2024-08-01 2025-07-31 14793248 ns10:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 14793248 ns10:FullAccounts 2024-08-01 2025-07-31 14793248 ns10:CompanySecretary1 2024-08-01 2025-07-31 14793248 ns10:RegisteredOffice 2024-08-01 2025-07-31 14793248 ns5:CurrentFinancialInstruments 2025-07-31 14793248 ns5:CurrentFinancialInstruments 2024-07-31 14793248 ns5:ShareCapital 2025-07-31 14793248 ns5:ShareCapital 2024-07-31 14793248 ns5:RetainedEarningsAccumulatedLosses 2025-07-31 14793248 ns5:RetainedEarningsAccumulatedLosses 2024-07-31 14793248 1 2024-08-01 2025-07-31 14793248 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-07-31 14793248 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-07-31

REGISTERED NUMBER: 14793248 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JULY 2025

FOR

TRUTINA THERAPEUTICS LTD

TRUTINA THERAPEUTICS LTD (REGISTERED NUMBER: 14793248)

CONTENTS OF THE FINANCIAL STATEMENTS

for the Year Ended 31 July 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 3 |

TRUTINA THERAPEUTICS LTD

COMPANY INFORMATION

for the Year Ended 31 July 2025

| DIRECTOR: | Professor J A Huntington

| SECRETARY: | The Cambridge Partnership Limited

| REGISTERED OFFICE: | C/o The Cambridge Partnership Ltd

| The Dorothy Hodgkin Building

| Babraham Research Campus, Babraham

| Cambridge

| Cambridgeshire

| CB22 3FH

| REGISTERED NUMBER: | 14793248 (England and Wales)

| ACCOUNTANTS: | Lovetts Accountants Limited

| Bridge House

| 25 Fiddlebridge Lane

| Hatfield

| Hertfordshire

| AL10 0SP

TRUTINA THERAPEUTICS LTD (REGISTERED NUMBER: 14793248)

BALANCE SHEET

31 July 2025

| 31.7.25 |  | 31.7.24

| Notes | £ | £ |

CURRENT ASSETS

Debtors | 4 | 17,129 |  | 46,741 |  |

Cash at bank and in hand | 54,382 |  | 48,147 |  |

71,511 |  | 94,888 |  |

CREDITORS

Amounts falling due within one year | 5 | 320,296 |  | 265,361 |  |

NET CURRENT LIABILITIES | (248,785 | ) | (170,473 | ) |

TOTAL ASSETS LESS CURRENT LIABILITIES | (248,785 | ) | (170,473 | ) |

CAPITAL AND RESERVES

Called up share capital | 1 |  | 1 |  |

Retained earnings | (248,786 | ) | (170,474 | ) |

SHAREHOLDERS' FUNDS | (248,785 | ) | (170,473 | ) |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 July 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 July 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 22 April 2026 and were signed by:

Professor J A Huntington - Director

TRUTINA THERAPEUTICS LTD (REGISTERED NUMBER: 14793248)

NOTES TO THE FINANCIAL STATEMENTS

for the Year Ended 31 July 2025

1. | STATUTORY INFORMATION

| Trutina Therapeutics Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Accounting judgements and key sources of estimation uncertainty

| The preparation of the financial statements requires the directors to make judgements, estimates and assumptions that can affect the amounts reported for assets and liabilities and the results for the year.

| The nature of estimation is such that the actual outcomes could differ significantly from those estimates.

| The following judgements have had the most significant impact on amounts recognised in the financial statements:

| Convertible debt

| The company has issued convertible loans. The loan has been allocated in its entirety to debt. At this point in time it is unclear how much will be converted in to equity.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Research and development

| Expenditure on research and development is written off in the year in which it is incurred.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 1 (2024 - 1 ) .

TRUTINA THERAPEUTICS LTD (REGISTERED NUMBER: 14793248)

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 31 July 2025

4. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 31.7.25 |  | 31.7.24

£ | £ |

| Other debtors | 17,129 |  | 46,741 |  |

5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 31.7.25 |  | 31.7.24

£ | £ |

| Trade creditors | 2,820 |  | 13,840 |  |

| Other creditors | 317,476 |  | 251,521 |  |

320,296 |  | 265,361 |  |